22nd Century Group (NASDAQ: XXII) — Perfil da empresa, notícias e dados financeiros
22nd Century Group focuses on biotechnology, reducing smoking harm through low-nicotine tobacco products and cannabis research.
22nd Century Group
22nd Century Group (NASDAQ:XXII) focuses on biotechnology, striving to decrease the harm caused by smoking through its proprietary tobacco products that have reduced nicotine content. Additionally, the company works on hemp/cannabis research to develop new plant varieties with specific cannabinoid profiles. With a mission geared towards improving health and reducing the impacts of smoking, 22nd Century Group is dedicated to advancing agricultural biotechnology projects and bringing to market tobacco with potentially less addictive properties, alongside exploring the growing potentials of cannabis for various uses. This combination of objectives underscores their commitment to public health and innovation in plant science.
Resumo
Operações
Produtos e/ou serviços de 22nd Century Group
- VLN cigarettes, designed to contain 95% less nicotine compared to traditional cigarettes, aiming to help smokers reduce their nicotine consumption.
- Development of proprietary tobacco plants with non-addictive levels of nicotine, to support the creation of reduced-risk tobacco products.
- Research and production of hemp/cannabis plants with specific cannabinoid profiles for medical, wellness, and pharmaceutical applications.
- Genetically engineered tobacco and hemp plants for improved crop yields and resistance to diseases and pests, enhancing agricultural efficiency.
- Sublicensing of their technology and plant varieties to other companies in the tobacco and hemp industries, diversifying their revenue streams.
- Consultancy services for biotechnology and agricultural firms, leveraging their expertise in plant biotechnology and genetics.
equipe executiva do 22nd Century Group
- Lawrence D. FirestonePresident, CEO & Chairman
- Daniel A. OttoCFO & Principal Accounting Officer
- Scott MarionVice President of Operations
- Jonathan StaffeldtGeneral Counsel & Secretary
- Robert P. ManfredoniaExecutive Vice President of Sales
- Kimberly FarrDirector of Science & Technology
- Katherine Rouse-BaileyVice President of Marketing
- Matthew KrepsInvestor Relations
- James C. MorrisonTechnical Advisor & Regulatory Affairs Consultant
Últimas notícias sobre a 22nd Century Group
Principais indicadores financeiros
Resultados divulgados pela 22nd Century Group, em USD.
- Cap. de mercado
- 2 mi
- Receita (TTM)
- 5,2 mi
- P/L
- 0.0
- LPA (diluído, TTM)
- 78.1
- Dividend yield
- —
- Margem de lucro
- -76.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 7 mi | -11,4 mi | -5,1 mi | |
| 11,9 mi | -14 mi | -15,2 mi | |
| 32,2 mi | -44,9 mi | -140,8 mi | |
| 40,5 mi | -33,6 mi | -59,8 mi |